First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04622774
• Other study ID #: IMGC936-0901
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: October 26, 2020
• Est. completion date: December 31, 2023

Study information

• Verified date: March 2024
• Source: ImmunoGen, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.

Description:

This is an open-label, dose-escalation, and expansion study to determine the Maximum Tolerated Dose (MTD) and select the recommended phase 2 dose. Dose escalation follows a conventional 3+3 design; successive cohorts of 3 to 6 participants each will be evaluated in sequential escalating doses of single-agent IMGC936. Upon completion of the dose-escalation phase of the study, following determination of the recommended Phase 2 dose (RP2D), up to 5 expansion cohorts may be opened in tumor types selected from those enrolled in dose escalation. Participants with relapsed or refractory, unresectable locally advanced or metastatic solid tumors including non-squamous non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), gastroesophageal cancer, or pancreatic cancer will be enrolled. IMGC936 is administered via intravenous (IV) infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter, at the assigned dose for each cohort during dose escalation, and at the RP2D for expansion. Infusion duration will vary depending on dose and participant tolerability. Sentinel dosing will be used for the first 2 dose levels of dose escalation. The first administration of IMGC936 in participants at the first 2 dose levels of dose escalation will be staggered by at least 48 hours. The dose-limiting toxicity (DLT) evaluation period is 21 days. Participants may continue on study drug until disease progression, adverse event (AE) requiring discontinuation, DLT during evaluation window, pregnancy, death, investigator decision, lost to follow up (LTFU), major protocol deviation requiring discontinuation, withdrawal of consent, or sponsor, investigator or regulatory agency terminates the study. Tumor assessments are performed every 6 weeks (Q6W) while on study drug then every 12 weeks (Q12W). Tumor assessments continue until discontinuation criteria are met. If feasible, participants who discontinue study drug for reasons other than progressive disease (PD) (e.g., toxicity) should continue to undergo tumor assessments Q12W as post-treatment follow up until evidence of PD, initiation of another anticancer therapy, withdrawal of consent, LTFU, death, or end of study. Post-treatment follow up also includes following ongoing treatment emergent adverse events (TEAEs) until the event has resolved to baseline grade, the event is assessed by the investigator as stable, initiations of another anticancer therapy, withdrawal of consent, LTFU, death, or it has been determined that study drug or participation is not the cause of the AE.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participants with histologically proven, relapsed or refractory, unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), gastroesophageal cancer, or pancreatic cancer for whom no therapy with demonstrated clinical benefit is available.

1. NSCLC: Participants must have been treated with 1 to 4 prior lines of systemic therapy with no more than 2 chemotherapy containing lines.

2. TNBC: Participants must have been treated with 1 to 4 prior lines of systemic therapy for metastatic disease, excluding adjuvant therapies.

3. CRC: Participants must have been treated with 1 to 3 prior lines of systemic therapy.

4. Gastroesophageal cancer: Participants must have been treated with 1 to 3 prior lines of systemic therapy.

5. Pancreatic cancer: Participants must have been treated with 1 to 3 prior lines of systemic therapy, with no more than 2 chemotherapy containing lines.

2. Either measurable or non-measurable disease per RECIST 1.1 and documented by computed tomography (CT) and/or magnetic resonance imaging (MRI) obtained within 28 days of C1D1.

• Dose escalation: Participants may have non-measurable or measurable disease
• Dose expansion: Participants must have measurable disease

3. Age = 18 years old.

4. Archival formalin-fixed paraffin-embedded (FFPE) tissue must be available. Participants may undergo a fresh tumor biopsy using a low risk, medically routine procedure to obtain a specimen for testing if a tumor sample is not available.

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. If ECOG performance status is an inappropriate performance measurement for participant enrollment (eg, chronically non-ambulatory), then Karnofsky performance status must be = 70.

6. Life expectancy = 12 weeks.

7. Acceptable laboratory parameters as follows:

• Platelet count = 75 × 1000/µL without transfusion within 28 days prior to initiation of study drug.
• Absolute neutrophil count = 1.5 × 1000/µL in the absence of any growth factor support within 21days prior to initiation of study drug.
• Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) = 3.0 × upper limit of normal (ULN); for participants with hepatic metastases, ALT and AST = 5 × ULN.
• Total bilirubin = 1.5 × ULN, except participants with Gilbert's syndrome, who may enroll if the conjugated bilirubin is within normal limits.
• Estimated glomerular filtration rate (eGFR) >30mL/min/1.73m2 or an estimated creatinine clearance of >30 mL/min.
• Urinalysis protein and white occult blood cells within normal limits.
• Negative serum pregnancy test for females of childbearing potential (FOCBP).

8. FOCBP, defined as not surgically sterilized (hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) and between menarche and 1-year post menopause, must have a negative serum pregnancy test performed within 72 hours prior to initiation of study drug administration. Female participants must abstain from egg donation during the study.

9. FOCBP and male participants with partners of FOCBP must agree to use highly effective methods of contraception, from the time of consent through 28 weeks after discontinuation of study drug administration. Male participants must abstain from sperm donation during the study.

10. FOCBP is not pregnant or breastfeeding, or a male participant is not expecting to father children within the projected duration of the study, starting with screening visit through 28 weeks after the last dose of study drug.

Exclusion Criteria:

1. Active central nervous system (CNS) disease within the last 6 months.

2. Active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision.

3. Participants who had prior therapies within the specified times below:

• Systemic antineoplastic therapy at least 5 half-lives or 4 weeks (whichever is shorter) prior to initiation of study drug.
• Mediastinal or pelvic radiation therapy within 6 weeks prior to initiation of study drug administration. Palliative, limited field radiation for symptom control to soft tissues, or bone lesions within 2 weeks prior to initiation of study drug.

4. Participants must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities (except alopecia).

5. Clinically significant cardiovascular disease including but not limited to:

• Myocardial infarction or unstable angina within 6 months prior to initiation of study drug.
• Stroke or transient ischemic attack within 6 months prior to initiation of study drug.
• Current clinically significant cardiac arrhythmias, e.g., atrial fibrillation that are not well controlled with optimal medical intervention.
• Current uncontrolled hypertension: systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg.
• Current congestive heart failure (New York Heart Association class III-IV).
• Current pericarditis or clinically significant pericardial effusion.
• Current myocarditis.
• Left ventricular ejection fraction (LVEF) of < 50% by scan
• QTc interval > 480 msec

6. Clinically significant pulmonary compromise, including pneumonia, pneumonitis, or a requirement for supplemental oxygen (excluding for sleep apnea) or history of = Grade 3 drug-induced or radiation pneumonitis.

7. Serious concurrent illness or clinically relevant active infection, including, but not

limited to the following:

• Active hepatitis B or C infection (whether or not on active antiviral therapy).
• Human immunodeficiency virus infection.
• Cytomegalovirus infection.
• Active COVID-19/SARS-CoV-2 infection. While SARS-CoV-2 testing is not mandatory for study entry, testing should follow local clinical practice guidelines/standards.
• Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to initiation of study drug.

8. History of prior bone marrow, stem cell, or solid organ transplantation.

9. Second primary invasive malignancy that has not been in remission for greater than 2 years except nonmelanoma skin cancer; cervical carcinoma in situ on biopsy; or squamous intraepithelial lesion on Pap smear; localized prostate cancer (Gleason score < 6); or resected melanoma in situ.

10. Major trauma or major surgery within 4 weeks prior to initiation of study drug.

11. Any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the study site.

12. Known hypersensitivity to any ingredient or any excipient contained in the drug formulation

13. Vaccination with any live virus vaccine within 4 weeks prior to initiation of study drug. Inactivated annual influenza vaccination is allowed.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• IMGC936
Antibody Drug Conjugate

Locations

Country	Name	City	State
Italy	Policlinico di Modena	Modena
Italy	IRCCS Humanitas	Rozzano
Italy	Azienda Ospedaliera Universitaria Senese	Siena
Spain	Hospital Universitario Quirónsalud Madrid	Madrid
Spain	START Madrid-FJD Hospital Universitario Fundacion Jimenez Diaz	Madrid
Spain	START Madrid-HM CIOCC	Madrid
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Sarah Cannon Research Institute	Denver	Colorado
United States	MD Anderson Cancer Center	Houston	Texas
United States	UCSD	La Jolla	California
United States	Stephenson Cancer Center	Oklahoma City	Oklahoma
United States	Washington University	Saint Louis	Missouri
United States	Florida Cancer Specialists	Sarasota	Florida

Sponsors (2)

Lead Sponsor	Collaborator
ImmunoGen, Inc.	MacroGenics

Countries where clinical trial is conducted

United States,  Italy,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	During dose escalation measure incidence and severity of Treatment Emergent Adverse Events by CTCAE v5.0	Number of treatment emergent adverse events as assessed by CTCAE v5.0	From screening to end of study (approximately up to 2 years) for each patient
Primary	During dose escalation characterize dose-limiting toxicities (DLTs)	Incidence of DLTs	DLT evaluation period is through cycle 1 (21 days)
Primary	During expansion describe the Overall Response Rate for IMGC936 using RECIST v1.1	Time to progression of disease using RECIST v1.1	From screening to end of study (approximately up to 2 years) for each patient
Secondary	During dose escalation and expansion to characterize study drug concentration	Study drug concentration	There are 9 blood draw collection time points at Cycles 1 and 3, 3 blood draw time points at Cycles 2,4,5 and 6, and collection at every 3 cycles after cycle 6 until end of study (approximately up to 2 years). Each cycle is 21 days.
Secondary	During dose escalation and expansion to measure the concentration of anti-drug antibody	Anti-drug antibody	There are 2 collection time points at Cycles 1 and 3, 1 collection time point at Cycles 2, 4, 5 and 6, and and collection at every 3 cycles after cycle 6 until end of study (approximately up to 2 years). Each cycle is 21 days.
Secondary	During dose expansion describe the duration of response and progression free survival	Time to disease progression	From screening to end of study (approximately up to 2 years) for each patient
Secondary	During dose escalation to describe the objective response rate and duration of response	Time to disease progression	From screening to end of study (approximately up to 2 years) for each patient
Secondary	During dose expansion measure incidence and severity of Treatment Emergent Adverse Events by CTCAE v5.0	Number of treatment emergent adverse events as assessed by CTCAE v5.0	From screening to end of study (approximately up to 2 years) for each patient